Online inquiry

IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8202MR)

This product GTTS-WQ8202MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLC39A6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001099406.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 25800
UniProt ID Q13433
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8202MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6362MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ11091MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ5751MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ9040MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ11569MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MG-A271
GTTS-WQ8843MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ14417MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ7288MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FPA-008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW